Fortis Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-13,800
Closed -$1.87M 133
2021
Q2
$1.87M Buy
+13,800
New +$1.81M 0.95% 58

Other funds holding XBI

Fortis Capital Management's XBI Position: Q3 2021 in Review

Fortis Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 13,800 shares — an estimated $1.87M sold.

Fortis Capital Management first reported a position in XBI in Q2 2021 and held it in 1 quarter. The position peaked at $1.87M in Q2 2021. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

  • Fortis Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
  • Fortis Capital Management sold 13,800 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $1.87M.
  • Fortis Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 1 quarter.
  • Fortis Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.87M in Q2 2021.
  • 635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Fortis Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.